期刊
EMERGING MICROBES & INFECTIONS
卷 10, 期 1, 页码 874-884出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2021.1921621
关键词
COVID-19; SARS-CoV-2; linker-immunodominant site; spike protein; vaccine
资金
- Health and Medical Research Fund [COVID190117]
- Shenzhen Peacock Plan [KQTD2015033117210153]
The S-ID vaccine candidate induced better neutralizing antibody response and showed reduced body weight loss, lung viral load, and histopathological changes in hamsters, suggesting its potential as an effective COVID-19 vaccine.
The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, we designed two linkerimmunodominant site (LIS) vaccine candidates which are composed of four immunodominant sites within the RBD (RBD-ID) or all the 10 immunodominant sites within the whole spike (S-ID). They were administered by subcutaneous injection and were tested for immunogenicity and in vivo protective efficacy in a hamster model for COVID-19. We showed that the S-ID vaccine induced significantly better neutralizing antibody response than RBD-ID and alum control. As expected, hamsters vaccinated by S-ID had significantly less body weight loss, lung viral load, and histopathological changes of pneumonia. The S-ID has the potential to be an effective vaccine for protection against COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据